Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

by Wu, Yi-Long , He, Jie , Zeng, Lingmin , John, Thomas , de Marinis, Filippo , Rukazenkov, Yuri , Grohe, Christian , Tsuboi, Masahiro , Majem, Margarita , Laktionov, Konstantin , Bonanno, Laura , Kato, Terufumi , Lee, Kye-Young , Shepherd, Frances A , Domine, Manuel , Lu, Shun , Hodge, Rachel , Goldman, Jonathan W , Atasoy, Ajlan , Vu, Huu-Vinh , Herbst, Roy S , Kim, Sang-We , Yu, Chong-Jen , Akewanlop, Charuwan

in Acrylamides - adverse effects / Acrylamides - therapeutic use / Adult / Aged / Aged, 80 and over / Aniline Compounds - adverse effects / Aniline Compounds - therapeutic use / Antineoplastic Agents - adverse effects / Antineoplastic Agents - therapeutic use / Cancer therapies / Carcinoma, Non-Small-Cell Lung - drug therapy / Carcinoma, Non-Small-Cell Lung - genetics / Carcinoma, Non-Small-Cell Lung - mortality / Carcinoma, Non-Small-Cell Lung - surgery / Central nervous system / Central nervous system diseases / Chemotherapy / Chemotherapy, Adjuvant / Committees / Death / Disease-Free Survival / Double-Blind Method / Epidermal growth factor / Epidermal growth factor receptors / ErbB Receptors - genetics / Female / Humans / Lung cancer / Lung Neoplasms - drug therapy / Lung Neoplasms - genetics / Lung Neoplasms - mortality / Lung Neoplasms - surgery / Lymphatic Metastasis / Male / Middle Aged / Mutation / Neoplasm Recurrence, Local / Neoplasm Staging / Non-small cell lung carcinoma / Patients / Pneumonectomy / Protein Kinase Inhibitors - adverse effects / Protein Kinase Inhibitors - therapeutic use / Safety / Small cell lung carcinoma / Statistical analysis / Targeted cancer therapy

2020

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

2020

Confirm

Do you wish to request the book?

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

2020

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

Wu, Yi-Long,

He, Jie,

Zeng, Lingmin,

John, Thomas,

de Marinis, Filippo,

Rukazenkov, Yuri,

Grohe, Christian,

Tsuboi, Masahiro,

Majem, Margarita,

Laktionov, Konstantin,

Bonanno, Laura,

Kato, Terufumi,

Lee, Kye-Young,

Shepherd, Frances A,

Domine, Manuel,

Lu, Shun,

Hodge, Rachel,

Goldman, Jonathan W,

Atasoy, Ajlan,

Vu, Huu-Vinh,

Herbst, Roy S,

Kim, Sang-We,

Yu, Chong-Jen,

Akewanlop, Charuwan

2020

Overview

The incidence of recurrence after curative resection among patients with stage IB, II, or IIIA non–small-cell lung cancer is high and is only slightly lower with adjuvant chemotherapy. A randomized trial of adjuvant osimertinib involving patients with EGFR mutation–positive NSCLC showed a substantial decrease in recurrence. Central nervous system relapses were also significantly reduced.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Acrylamides - adverse effects

/ Acrylamides - therapeutic use

/ Adult

/ Aged

/ Aged, 80 and over

/ Aniline Compounds - adverse effects

/ Aniline Compounds - therapeutic use